Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis (PsA). POETYK PsA-1 (ClinicalTrials.gov ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

A Bristol Myers Squibb drug that was first in its class to hit a certain immunological target now has positive data from two pivotal tests in psoriatic arthritis that could support expanding use ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

US pharma major Bristol Myers Squibb has announced positive results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055 ...